Insmed Incorporated (INSM)

$24.11

-0.21

(-0.86%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Insmed Incorporated

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 59.3M → 83.69M (in $), with an average increase of 8.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -158.93M → -186.06M (in $), with an average decrease of 17.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 8.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 261.9%

Performance

  • $24.01
    $24.95
    $24.11
    downward going graph

    0.41%

    Downside

    Day's Volatility :3.77%

    Upside

    3.37%

    downward going graph
  • $17.41
    $32.00
    $24.11
    downward going graph

    27.79%

    Downside

    52 Weeks Volatility :45.59%

    Upside

    24.66%

    downward going graph

Returns

PeriodInsmed IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
-14.76%
-0.7%
0.0%
6 Months
-2.33%
9.2%
0.0%
1 Year
28.61%
3.5%
-1.3%
3 Years
-30.55%
12.3%
-22.1%

Highlights

Market Capitalization
3.6B
Book Value
- $2.24
Earnings Per Share (EPS)
-5.34
PEG Ratio
0.0
Wall Street Target Price
43.87
Profit Margin
-245.59%
Operating Margin TTM
-194.25%
Return On Assets TTM
-28.5%
Return On Equity TTM
-1453.41%
Revenue TTM
305.2M
Revenue Per Share TTM
2.17
Quarterly Revenue Growth YOY
41.099999999999994%
Gross Profit TTM
190.2M
EBITDA
-672.5M
Diluted Eps TTM
-5.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.6
EPS Estimate Next Year
-3.8
EPS Estimate Current Quarter
-1.15
EPS Estimate Next Quarter
-1.2

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Insmed Incorporated(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
18
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 81.96%

Current $24.11
Target $43.87

Company Financials

FY18Y/Y Change
Revenue
9.8M
-
Net Income
-324.3M
↑ 68.33%
Net Profit Margin
-3.3K%
-
FY19Y/Y Change
Revenue
136.5M
↑ 1287.56%
Net Income
-254.3M
↓ 21.57%
Net Profit Margin
-186.37%
↑ 3110.8%
FY20Y/Y Change
Revenue
164.4M
↑ 20.48%
Net Income
-294.1M
↑ 15.63%
Net Profit Margin
-178.87%
↑ 7.5%
FY21Y/Y Change
Revenue
188.5M
↑ 14.63%
Net Income
-434.7M
↑ 47.8%
Net Profit Margin
-230.63%
↓ 51.76%
FY22Y/Y Change
Revenue
245.4M
↑ 30.19%
Net Income
-481.5M
↑ 10.79%
Net Profit Margin
-196.26%
↑ 34.37%
FY23Y/Y Change
Revenue
305.2M
↑ 24.39%
Net Income
-749.6M
↑ 55.66%
Net Profit Margin
-245.59%
↓ 49.33%
Q3 FY22Q/Q Change
Revenue
67.7M
↑ 3.85%
Net Income
-131.1M
↑ 37.12%
Net Profit Margin
-193.63%
↓ 46.98%
Q4 FY22Q/Q Change
Revenue
59.3M
↓ 12.45%
Net Income
-160.1M
↑ 22.1%
Net Profit Margin
-270.02%
↓ 76.39%
Q1 FY23Q/Q Change
Revenue
65.2M
↑ 9.97%
Net Income
-159.8M
↓ 0.22%
Net Profit Margin
-244.98%
↑ 25.04%
Q2 FY23Q/Q Change
Revenue
77.2M
↑ 18.42%
Net Income
-244.8M
↑ 53.23%
Net Profit Margin
-316.99%
↓ 72.01%
Q3 FY23Q/Q Change
Revenue
79.1M
↑ 2.39%
Net Income
-158.9M
↓ 35.08%
Net Profit Margin
-201.0%
↑ 115.99%
Q4 FY23Q/Q Change
Revenue
83.7M
↑ 5.84%
Net Income
-186.1M
↑ 17.07%
Net Profit Margin
-222.31%
↓ 21.31%
FY18Y/Y Change
Total Assets
604.6M
↑ 30.84%
Total Liabilities
396.3M
↑ 292.41%
FY19Y/Y Change
Total Assets
742.3M
↑ 22.78%
Total Liabilities
480.6M
↑ 21.28%
FY20Y/Y Change
Total Assets
796.2M
↑ 7.26%
Total Liabilities
520.3M
↑ 8.25%
FY21Y/Y Change
Total Assets
1.2B
↑ 56.19%
Total Liabilities
833.0M
↑ 60.12%
FY22Y/Y Change
Total Assets
1.7B
↑ 33.21%
Total Liabilities
1.6B
↑ 88.28%
FY23Y/Y Change
Total Assets
1.3B
↓ 19.72%
Total Liabilities
1.7B
↑ 5.95%
Q3 FY22Q/Q Change
Total Assets
994.8M
↓ 5.56%
Total Liabilities
1.0B
↑ 1.55%
Q4 FY22Q/Q Change
Total Assets
1.7B
↑ 66.51%
Total Liabilities
1.6B
↑ 53.06%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 8.37%
Total Liabilities
1.6B
↓ 0.39%
Q2 FY23Q/Q Change
Total Assets
1.4B
↓ 5.18%
Total Liabilities
1.6B
↑ 2.08%
Q3 FY23Q/Q Change
Total Assets
1.3B
↓ 7.94%
Total Liabilities
1.6B
↑ 1.21%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 0.37%
Total Liabilities
1.7B
↑ 2.94%
FY18Y/Y Change
Operating Cash Flow
-258.0M
↑ 61.62%
Investing Cash Flow
-14.8M
↑ 393.64%
Financing Cash Flow
386.7M
↑ 1.48%
FY19Y/Y Change
Operating Cash Flow
-250.6M
↓ 2.84%
Investing Cash Flow
-42.3M
↑ 185.32%
Financing Cash Flow
285.3M
↓ 26.24%
FY20Y/Y Change
Operating Cash Flow
-219.3M
↓ 12.49%
Investing Cash Flow
-6.8M
↓ 83.86%
Financing Cash Flow
271.0M
↓ 5.0%
FY21Y/Y Change
Operating Cash Flow
-363.3M
↑ 65.63%
Investing Cash Flow
-64.3M
↑ 842.32%
Financing Cash Flow
612.5M
↑ 126.03%
FY22Y/Y Change
Operating Cash Flow
-400.4M
↑ 10.22%
Investing Cash Flow
-34.6M
↓ 46.2%
Financing Cash Flow
793.3M
↑ 29.5%
Q3 FY22Q/Q Change
Operating Cash Flow
-89.8M
↓ 12.19%
Investing Cash Flow
49.4M
↓ 1801.72%
Financing Cash Flow
37.1M
↑ 488.12%
Q4 FY22Q/Q Change
Operating Cash Flow
-103.1M
↑ 14.83%
Investing Cash Flow
20.3M
↓ 58.9%
Financing Cash Flow
743.4M
↑ 1902.87%
Q1 FY23Q/Q Change
Operating Cash Flow
-146.3M
↑ 41.84%
Investing Cash Flow
41.6M
↑ 104.85%
Financing Cash Flow
-399.0K
↓ 100.05%
Q2 FY23Q/Q Change
Operating Cash Flow
-122.8M
↓ 16.07%
Investing Cash Flow
-274.2M
↓ 759.0%
Financing Cash Flow
44.3M
↓ 11209.27%

Technicals Summary

Sell

Neutral

Buy

Insmed Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Insmed Incorporated
Insmed Incorporated
-7.98%
-2.33%
28.61%
-30.55%
-20.34%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Insmed Incorporated
Insmed Incorporated
NA
NA
0.0
-4.6
-14.53
-0.28
NA
-2.24
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Insmed Incorporated
Insmed Incorporated
Buy
$3.6B
-20.34%
NA
-245.59%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Vanguard Group Inc

    9.51%

  • BlackRock Inc

    7.74%

  • T. Rowe Price Associates, Inc.

    7.25%

  • State Street Corporation

    3.99%

  • T. Rowe Price Investment Management,Inc.

    3.94%

  • Palo Alto Investors, LLC

    3.71%

Corporate Announcements

  • Insmed Incorporated Earnings

    Insmed Incorporated’s price-to-earnings ratio stands at None

    Read More

Company Information

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Organization
Insmed Incorporated
Employees
912
CEO
Mr. William H. Lewis J.D., M.B.A.
Industry
Health Technology

Discover More

FAQs